Our present findings provide some rationale for looking outside the contemporary classification of TACSTD2 as an oncogene by highlighting several tumor suppressor traits that make TACSTD2 a putative, actionable biomarker that should be carefully considered when developing any meaningful anti-mCRPC therapeutic strategy. Here, TACSTD2 is linked to neoplasm.